Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Drug development company announces publication of Alzheimer preclinical studies
August 15th, 2005
Samaritan Pharmaceuticals Inc. (LIV) announced that the journal of NEUROPharmacology published Samaritan's preclinical studies evaluating drug candidates, SP-08 and its derivatives, as a possible new approach to fight against Alzheimer disease. Dr. Janet Greeson, CEO of Samaritan stated, "Alzheimer disease is a progressive condition which damages the areas of the brain involved in memory, intelligence, judgment, language skills and behavior. With Alzheimer, amyloid protein builds up in the brain and makes it difficult for one nerve cell to communicate with another." She added, "Our approach is to identify new experimental compounds that...
Source: Pharma Business Week (2005-08-15)
|
